135 related articles for article (PubMed ID: 18063258)
1. Therapy of chronic hepatitis B: focus on telbivudine.
Gaeta GB; Stornaiuolo G
Dig Liver Dis; 2007 Nov; 39 Suppl 3():S372-8. PubMed ID: 18063258
[TBL] [Abstract][Full Text] [Related]
2. Telbivudine in the treatment of chronic hepatitis B.
Nash K
Adv Ther; 2009 Feb; 26(2):155-69. PubMed ID: 19225726
[TBL] [Abstract][Full Text] [Related]
3. Telbivudine for the management of chronic hepatitis B virus infection.
Matthews SJ
Clin Ther; 2007 Dec; 29(12):2635-53. PubMed ID: 18201580
[TBL] [Abstract][Full Text] [Related]
4. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
Hou J; Yin YK; Xu D; Tan D; Niu J; Zhou X; Wang Y; Zhu L; He Y; Ren H; Wan M; Chen C; Wu S; Chen Y; Xu J; Wang Q; Wei L; Chao G; Constance BF; Harb G; Brown NA; Jia J
Hepatology; 2008 Feb; 47(2):447-54. PubMed ID: 18080339
[TBL] [Abstract][Full Text] [Related]
5. Treatment of chronic hepatitis B: focus on telbivudine.
Lui YY; Chan HL
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):259-68. PubMed ID: 19344240
[TBL] [Abstract][Full Text] [Related]
6. Telbivudine: an upcoming agent for chronic hepatitis B.
Yuen MF; Lai CL
Expert Rev Anti Infect Ther; 2005 Aug; 3(4):489-94. PubMed ID: 16107194
[TBL] [Abstract][Full Text] [Related]
7. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
[TBL] [Abstract][Full Text] [Related]
8. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
Liaw YF; Gane E; Leung N; Zeuzem S; Wang Y; Lai CL; Heathcote EJ; Manns M; Bzowej N; Niu J; Han SH; Hwang SG; Cakaloglu Y; Tong MJ; Papatheodoridis G; Chen Y; Brown NA; Albanis E; Galil K; Naoumov NV;
Gastroenterology; 2009 Feb; 136(2):486-95. PubMed ID: 19027013
[TBL] [Abstract][Full Text] [Related]
9. Telbivudine versus lamivudine in patients with chronic hepatitis B.
Lai CL; Gane E; Liaw YF; Hsu CW; Thongsawat S; Wang Y; Chen Y; Heathcote EJ; Rasenack J; Bzowej N; Naoumov NV; Di Bisceglie AM; Zeuzem S; Moon YM; Goodman Z; Chao G; Constance BF; Brown NA;
N Engl J Med; 2007 Dec; 357(25):2576-88. PubMed ID: 18094378
[TBL] [Abstract][Full Text] [Related]
10. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Evans A; Riva A; Cooksley H; Phillips S; Puranik S; Nathwani A; Brett S; Chokshi S; Naoumov NV
Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic hepatitis B: will entecavir and telbivudine do the trick?
Anand AC; Puri P
Trop Gastroenterol; 2008; 29(2):71-5. PubMed ID: 18972765
[TBL] [Abstract][Full Text] [Related]
12. Telbivudine for the treatment of chronic hepatitis B infection.
Hartwell D; Jones J; Harris P; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():23-30. PubMed ID: 19846025
[TBL] [Abstract][Full Text] [Related]
13. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B.
Chen Y; Li X; Ye B; Yang X; Wu W; Chen B; Pan X; Cao H; Li L
Antiviral Res; 2011 Jul; 91(1):23-31. PubMed ID: 21549152
[TBL] [Abstract][Full Text] [Related]
14. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.
Ma SW; Huang X; Li YY; Tang LB; Sun XF; Jiang XT; Zhang YX; Sun J; Liu ZH; Abbott WG; Dong YH; Naoumov NV; Hou JL
J Hepatol; 2012 Apr; 56(4):775-81. PubMed ID: 22173154
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic hepatitis B: Evolution over two decades.
Yuen MF; Lai CL
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
[TBL] [Abstract][Full Text] [Related]
16. Two patterns of alanine aminotransferase increase to predict long-term viral response in chronic hepatitis B patients: virus- or host-induced?
You H; Wu X; Ou X; Ma H; Wang Q; Liu T; Cong M; Wang P; Wang B; Jia J
Antivir Ther; 2011; 16(3):299-307. PubMed ID: 21555812
[TBL] [Abstract][Full Text] [Related]
17. Novel anti-hepatitis B agents: A focus on telbivudine.
Jones R; Nelson M
Int J Clin Pract; 2006 Oct; 60(10):1295-9. PubMed ID: 16981973
[TBL] [Abstract][Full Text] [Related]
18. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
[TBL] [Abstract][Full Text] [Related]
19. Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses.
Hann HW
Expert Opin Pharmacother; 2010 Sep; 11(13):2243-9. PubMed ID: 20698726
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy of nucleoside/nucleotide analogue on chronic hepatitis B].
Lin Q; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2009 Oct; 17(10):722-5. PubMed ID: 19874684
[No Abstract] [Full Text] [Related]
[Next] [New Search]
